Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Procedural PainBuprenorphineAdjuvants, AnesthesiaDilation and EvacuationAnalgesics
Interventions
DRUG

Buprenorphine 0.15 MG

Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.

DRUG

Lidocaine 1% Injectable Solution

20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.

Trial Locations (1)

92093

University of California San Diego Health, San Diego

All Listed Sponsors
collaborator

Society of Family Planning

OTHER

lead

University of California, San Diego

OTHER

NCT04254081 - Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion | Biotech Hunter | Biotech Hunter